Gyre Therapeutics vs Zhengye Biotechnology
GYRE and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GYRE and ZYBT compare
Gyre Therapeutics grew revenue faster over the last twelve months (−3.7% versus −37.6% for Zhengye Biotechnology).
Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −60.0% at Zhengye Biotechnology.
Gyre Therapeutics scores higher on the StockData Score (11 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GYRE | ZYBT |
|---|---|---|
| Size and price | ||
| Market cap | $490M | – |
| Share price | $4.39 | $1.43 |
| Change, 1 year | −45.7% | −33.5% |
| Change, 5 years | −76.6% | – |
| Beta (5Y) | 1.26 | 0.41 |
| Employees | 618 | 51 |
| StockData Score | ||
| Total score | 11 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.5× | – |
| P/B | 4.5× | – |
| FCF yield | −1.6% | – |
| Fair value | $5.35 | – |
| Margin of safety | 17.9% | – |
| Growth | ||
| Revenue growth (TTM) | −3.7% (better) | −37.6% |
| Revenue growth, 5Y average | 41.0% | – |
| Net income growth (TTM) | −801% | −717% (better) |
| Profitability | ||
| Gross margin | 93.4% (better) | 20.5% |
| Operating margin | −14.4% (better) | −60.6% |
| Net margin | −33.9% (better) | −60.0% |
| FCF margin | −7.2% | 10.6% (better) |
| Return on equity | −34.9% | −26.1% (better) |
| Return on invested capital | −26.6% | −18.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.26 (better) |
| Interest coverage | – | −20.7× |
| Current ratio | 4.32 (better) | 1.14 |
| Altman Z-score | 8.21 | – |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 7.8% | – |
| Held by insiders | 93.8% | 90.7% |
| Insider net buying, 12 months | −$953K | – |
| Short interest, % of float | 32.4% | – |
Go deeper
- GYRE stock overview
- GYRE income statement
- GYRE valuation and score
- ZYBT stock overview
- ZYBT income statement
- ZYBT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.